Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -9366.75% is 553% below its 3-year average of -1434.17%, near the low end of its 3-year range (-10039.18%–0.00%).
179.91% below its 12-month average of -3346.39%.
Reported quarterly profit margin; no daily interpolation. Q4 FY2025 (2025-12-31): -10039.18%.
NET PROFIT MARGIN
-9366.75%
NET PROFIT MARGIN AVG TTM
-3346.39%
NET PROFIT MARGIN AVG 3Y
-1434.17%
NET PROFIT MARGIN AVG 5Y
N/A
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-179.91%
CURRENT VS 3Y AVG
-553.11%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 431 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares
Market Cap
$6.03M
Net Profit Margin
-9366.75%
TTM Avg
-3346.39%
3Y Avg
-1434.17%
5Y Avg
N/A
Market Cap
$6.09M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
-86.55%
Market Cap
$6.10M
Net Profit Margin
-44771.83%
TTM Avg
-33930.36%
3Y Avg
-151894.64%
5Y Avg
-112740.11%
Market Cap
$6.10M
Net Profit Margin
-534.27%
TTM Avg
-983.65%
3Y Avg
-1060.24%
5Y Avg
-924.37%
Market Cap
$6.34M
Net Profit Margin
-84.79%
TTM Avg
-89.20%
3Y Avg
-105.63%
5Y Avg
-91.66%
Market Cap
$5.63M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$6.44M
Net Profit Margin
-1084.23%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$5.36M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$6.72M
Net Profit Margin
-611.47%
TTM Avg
-627.26%
3Y Avg
-917.71%
5Y Avg
-6297.45%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR) | $6.03M | -9366.75% | -3346.39% | -1434.17% | N/A |
| Enlivex Therapeutics Ltd. (ENLV)vs › | $6.09M | 0.00% | 0.00% | 0.00% | -86.55% |
| Cardio Diagnostics Holdings, Inc. (CDIO)vs › | $6.10M | -44771.83% | -33930.36% | -151894.64% | -112740.11% |
| Femasys Inc. (FEMY)vs › | $6.10M | -534.27% | -983.65% | -1060.24% | -924.37% |
| Biomerica, Inc. (BMRA)vs › | $6.34M | -84.79% | -89.20% | -105.63% | -91.66% |
| Acurx Pharmaceuticals, Inc. (ACXP)vs › | $5.63M | 0.00% | 0.00% | 0.00% | 0.00% |
| Ensysce Biosciences, Inc. (ENSC)vs › | $6.44M | -1084.23% | 0.00% | 0.00% | 0.00% |
| Alzamend Neuro Inc (ALZN)vs › | $5.36M | 0.00% | 0.00% | 0.00% | 0.00% |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.72M | -611.47% | -627.26% | -917.71% | -6297.45% |
| Aclarion, Inc. (ACON)vs › | $6.74M | -10978.48% | -12422.83% | -10763.38% | -10131.90% |
Operating Margin
-9154.6%
Net Profit Margin
-9366.8%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2025-12-31 | -10039.18% |
| 2025-06-30 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-06-30 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-06-30 | 0.00% |
| 2022-12-31 | 0.00% |
